Detalhe da pesquisa
1.
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
Mol Cancer Ther
; 18(7): 1323-1334, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31068384